Advertisement

Annals of Hematology

, Volume 91, Issue 5, pp 729–735 | Cite as

Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury

  • Nils Heyne
  • Barbara Denecke
  • Martina Guthoff
  • Katharina Oehrlein
  • Lothar Kanz
  • Hans-Ulrich Häring
  • Katja C. Weisel
Original Article

Abstract

Acute kidney injury (AKI) is frequent in multiple myeloma (MM) patients and strongly affects prognosis, with particularly poor outcomes in patients requiring hemodialysis. Introduction of the novel therapeutic agents to MM therapy has improved myeloma response and renal outcome. This case series reviews the efficacy of combined systemic and extracorporeal therapy to further optimize time to light chain (serum-free light chain (sFLC)) reduction and renal recovery in MM patients with dialysis-dependent AKI (n = 19). High cut-off (HCO) hemodialysis for extracorporeal sFLC removal was initiated in parallel to chemotherapy. Combined therapy resulted in early sFLC response after a median of 13 (range 4–48) days and 6 (3–22) HCO hemodialysis sessions. Time to sFLC response was shorter in patients recovering renal function. Median time to dialysis independence was 15 (4–64) days. By intent-to-treat analysis, sustained renal recovery was achieved in 73.7% (77.8% adjusted for death) of patients. In multivariate analysis, duration of AKI prior to initiation of therapy was an independent predictor of renal functional outcome. Combining HCO hemodialysis for extracorporeal sFLC elimination and effective chemotherapy is a novel treatment strategy allowing for early and sustained sFLC reduction and a high proportion of renal recovery in these patients. Timely diagnosis and onset of therapy is essential for improving renal outcome.

Keywords

Multiple myeloma Acute kidney injury Light chain elimination HCO hemodialysis Renal recovery 

Notes

Acknowledgements

HCO filters were provided courtesy of Gambro Dialysatoren GmbH, Hechingen, Germany.

Conflict of interest

The authors report no conflict of interest.

References

  1. 1.
    Alexanian R, Barlogie B, Dixon D (1990) Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 150:1693–1695PubMedCrossRefGoogle Scholar
  2. 2.
    Bladé J, Fernandez-Llama P, Bosch F, Montoliù J, Lens XM, Montoto S et al (1998) Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158:1889–1893PubMedCrossRefGoogle Scholar
  3. 3.
    Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21–33PubMedCrossRefGoogle Scholar
  4. 4.
    Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A et al (2007) Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 48:337–341PubMedCrossRefGoogle Scholar
  5. 5.
    Knudsen LM, Hjorth M, Hippe E (2000) Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 65:175–181PubMedCrossRefGoogle Scholar
  6. 6.
    Torra R, Blade J, Cases A, López-Pedret J, Montserrat E, Rozman C et al (1995) Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 91:854–859PubMedCrossRefGoogle Scholar
  7. 7.
    Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S et al (2009) Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 4:745–754PubMedCrossRefGoogle Scholar
  8. 8.
    Santostefano M, Zanchelli F, Zaccaria A, Poletti G, Fusaroli M (2005) The ultrastructural basis of renal pathology in monoclonal gammopathies. J Nephrol 18:659–675PubMedGoogle Scholar
  9. 9.
    Huang ZQ, Sanders PW (1995) Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab Invest 73:810–817PubMedGoogle Scholar
  10. 10.
    Ying WZ, Sanders PW (2001) Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol 158:1859–1866PubMedCrossRefGoogle Scholar
  11. 11.
    Sanders PW, Booker BB, Bishop JB, Cheung HC (1990) Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest 85:570–576PubMedCrossRefGoogle Scholar
  12. 12.
    Sanders PW, Booker BB (1991) Pathobiology of cast nephropathy from human Bence Jones proteins. N Engl J Med 324:1845–1851CrossRefGoogle Scholar
  13. 13.
    Blade J, Rosinol L (2005) Renal, hematologic and infectious complications in multiple myeloma. Best Pract Res Clin Haematol 18:635–652PubMedCrossRefGoogle Scholar
  14. 14.
    Basnayake K, Cheung CK, Sheaff M, Fuggle W, Kamel D, Nakoinz S et al (2010) Differential progression of renal scarring and determinants of late recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. J Clin Pathol 63:884–887PubMedCrossRefGoogle Scholar
  15. 15.
    Tsakiris DJ, Stel VS, Finne P, Fraser E, Heaf J, de Meester J et al (2010) Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry Study. Nephrol Dial Transplant 25:1200–1206PubMedCrossRefGoogle Scholar
  16. 16.
    Richardson PG, Barlogie B, Berenson J, Shingal S, Jagannath S, Irwin DH, SUMMIT Investigators et al (2005) Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 106:2977–2981PubMedCrossRefGoogle Scholar
  17. 17.
    Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al (2010) Lenalidomide plus high-dose dexamathasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11:29–37PubMedCrossRefGoogle Scholar
  18. 18.
    Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S et al (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28:4976–4984PubMedCrossRefGoogle Scholar
  19. 19.
    Johnson WJ, Kyle RA, Pineda AA, O’Brien PC, Holley KE (1990) Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis and chemotherapy. Arch Intern Med 150:863–869PubMedCrossRefGoogle Scholar
  20. 20.
    Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barret BJ et al (2005) Plasma exchange when myeloma presents as acute renal failure: a randomized controlled trial. Ann Intern Med 143:777–784PubMedGoogle Scholar
  21. 21.
    Weisel KC, Heyne N, Hutchison CA, Göhl H, Risler T, Kanz L (2007) Effective light chain elimination via a high cut-off protein permeable filter in patients with light chain myeloma disease. Onkologie 30(suppl 3):80Google Scholar
  22. 22.
    Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J et al (2007) Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 18:886–895PubMedCrossRefGoogle Scholar
  23. 23.
    Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) group. Crit Care 8:R204–R212PubMedCrossRefGoogle Scholar
  24. 24.
    Mehta RL, Kellum JA, Shah SV (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31PubMedCrossRefGoogle Scholar
  25. 25.
    Verfoord G, Willems HL, Wetzels JF (2002) Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrol Dial Transplant 17:1909–1913CrossRefGoogle Scholar
  26. 26.
    Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Mikou M, Matsuoka C et al (2009) Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens. Clin Lymphoma Myeloma 9:302–306PubMedCrossRefGoogle Scholar
  27. 27.
    Kidney Disease Outcomes Quality Initiative (K/DOQI) (2002) Executive summary. Am J Kidney Dis 39(suppl 1):S17–S31Google Scholar
  28. 28.
    Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, International Myeloma Working Group et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473PubMedCrossRefGoogle Scholar
  29. 29.
    Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485–1493PubMedCrossRefGoogle Scholar
  30. 30.
    Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S et al (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109:2604–2606PubMedCrossRefGoogle Scholar
  31. 31.
    Ludwig H, Drach J, Graf H, Lang A, Meran JG (2007) Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 92:1411–1414PubMedCrossRefGoogle Scholar
  32. 32.
    Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F et al (2010) Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 28:4635–4641PubMedCrossRefGoogle Scholar
  33. 33.
    Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Anagnostou D, Koureas A et al (2010) Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 85:1–5PubMedCrossRefGoogle Scholar
  34. 34.
    Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM et al (2010) The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 116:3807–3814PubMedCrossRefGoogle Scholar
  35. 35.
    Matsue K, Fujiwara H, Iwama KI, Kimura S, Yamakura M, Takeuchi M (2010) Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years. Ann Hematol 89:291–297PubMedCrossRefGoogle Scholar
  36. 36.
    Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsuoka C, Barmparousi D et al (2007) Reversibility of acute renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone containing regimens and the impact of novel agents. Haematologica 92:546–549PubMedCrossRefGoogle Scholar
  37. 37.
    Wynckel A, Vuiblet V, Schneider N, Kolb B, Melin JP, Journet J et al (2010) Comparison of plasma exchange and hemodialysis using a high cut-off membrane (HCO) for removal of immunoglobulin free light chains in multiple myeloma. J Am Soc Nephrol 21:39AGoogle Scholar
  38. 38.
    Hutchison CA, Cook M, Heyne N, Weisel KC, Billingham L, Bradwell A et al (2008) European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE). A randomised control trial. Trials 9:55PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Nils Heyne
    • 1
  • Barbara Denecke
    • 2
  • Martina Guthoff
    • 1
  • Katharina Oehrlein
    • 2
  • Lothar Kanz
    • 2
  • Hans-Ulrich Häring
    • 1
  • Katja C. Weisel
    • 2
  1. 1.Department of Endocrinology and Diabetology, Angiology, Nephrology and Clinical ChemistryUniversity of TübingenTübingenGermany
  2. 2.Department of Hematology, Oncology and ImmunologyUniversity of TübingenTübingenGermany

Personalised recommendations